Managing persistent corneal epithelial defects, a common and challenging issue in ophthalmology, was traditionally tackled through a variety of treatments. These range from frequent lubrication and immunomodulators to more advanced methods like pressure patching, epithelial debridement, scleral contact lenses, and amniotic membrane transplantation (AMT). Recently, researchers have been exploring the benefits of combining eyelid pressure patching with AMT for more effective and efficient treatment.

Kyle Linsey analyzed 144 eyes treated with a therapeutic approach that combined eyelid pressure patching with AMT. The results offered a groundbreaking perspective: a new approach that showed promise in treating corneal epithelial defects.

A Review of Traditional Treatments for Corneal Epithelial Defects

The existing therapeutic approaches for persistent corneal epithelial defects include frequent lubrication, immunomodulators, steroids, autologous serum or platelet-rich plasma tears, bandage contact lenses, punctal occlusion, pressure patching, epithelial debridement, scleral contact lenses, cenegermin, and AMT. Individuals suffering from these issues may find these treatments inadequate as they often lead to discomfort, repeated procedures, and varying degrees of effectiveness. The study by Linsey highlighted underutilized synergistic properties leading to increased success rates.

Advantages of Amniotic Membrane Tissue (AMT)

The amniotic membrane’s unique properties include rapid re-epithelialization, addressing ocular surface inflammation, promoting repair of damaged tissue, and shielding defects from external factors. These attributes make AMT a valuable asset in various ophthalmologic applications, providing a dynamic tool to promote healing and regeneration. The rapid re-epithelialization rates, which range from 45.5% to 74.7%, demonstrate AMT’s efficacy regardless of the ulcer’s origin. Linsey explained, “AMT supports damaged tissue, protects and shields defects from further degeneration or breakdown from external factors, and promotes re-cellularization.”

The research highlighted some compelling points: AMT stimulates the proliferation and migration of limbal stem cells, suppresses neo-angiogenesis, inflammation, and scarring, and contributes to the healing of ocular surface disease. It physically acts as a substrate for epithelial cell growth and has been found to be more effective than autologous serum.

Additionally, while AMT does not transfer viable stem cells, it functions to support and protect the affected ocular surface, acting as a scaffold for donor–recipient cell migration and integration.

Recent Findings and Practical Applications

Recent findings underline the profound impact of combining AMT with eyelid pressure patching on treating persistent corneal epithelial defects. Linsey’s study on 144 eyes assessed two treatment methods: using a single-layer or three-layer decellularized amniotic basement membrane combined with a 24-hour eyelid pressure patch. The majority of cases (90%) were treated with a single layer, while 10% received three layers.

The outcomes were striking. The single-layer group reported complete healing and dissolution of the AMBM. Conversely, the three-layer group reported significant improvements in corneal staining with a dissolution rate of 20% to 30% incomplete in cases. Notably, the study reports no instances of pain, discomfort, or infection. These points underscore the effective and safe nature of this approach.

Linsey states “AMT promotes epithelial cell proliferation, reduces inflammation and neuropathic pain, and limits scar formation.” Additionally, “AMT can act as a mechanical barrier to protect the ocular surface, prevent evaporation and dryness, and maintain a stable tear film while serving as a scaffold for donor–recipient cell migration and integration. The integration of an eyelid pressure patch with dehydrated, decellularized amniotic membrane(AMT) treatment for advanced ocular surface disease leads to accelerated corneal healing and increased patient comfort.”

Broader Implications and Further Research

The potential impact of this therapeutic approach extends beyond immediate treatment success. With an aging population in the U.S. and increasing prevalence of corneal diseases, such innovative methods could significantly reduce patient discomfort and healthcare costs, allowing further allocations for preventative care and eye screening programs.

Yet, it’s vital to recognize potential limitations. While the study demonstrates high efficacy and safety, further corroborative randomized subject trials and longitudinal studies are needed to establish these results’ generalizability and long-term benefits. Future investigations could compare the efficacy of single-layer versus multi-layer treatments over longer periods. Additionally, cost-utility analyses could evaluate the comparative financial feasibility of different treatment options.

Overall, the integration of AMT with eyelid pressure patching represents a significant advancement in managing ocular surface diseases. It underscores the potential of synergistic therapeutic approaches and encourages further exploration for more effective and comfortable treatments for patients.

Real-World Application:

Dr. Emily Jones, an optometrist in San Francisco has utilized AM tissue extensively in the treatment of persistent corneal defects. In some cases, her practice also combines the therapy with other supportive treatments, she said “My experience has shown improved cellular restoration and reduced ocular recession.”

References

1. Katizin JR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol 2014;28:168-72
   

2. Ljubimov of, Saghizadeh M. Progress in Corneal Wound Healing. Prog Retin Eye Res. 2015;49:17-45